Brickner Anthony G
Department of Medicine, University of Pittsburgh Cancer Institute, Pittsburgh, PA 15213-1863, USA.
Immunol Res. 2006;36(1-3):33-41. doi: 10.1385/IR:36:1:33.
Minor histocompatibility antigens (mHAgs) are a diverse collection of major histocompatibility complex (MHC)-bound peptides that play a critical role in the induction of detrimental graft-versus-host disease (GVHD) or the development of beneficial graft-versustumor (GVT) effects after allogeneic hematopoietic stem cell transplantation. mHAgs are a consequence of allelic polymorphism that translates to disparity in MHC-presented peptide epitopes between transplant donor and recipient. This donor/recipient allelic disparity can range from infinitesimal amino side chain differences between MHC-presented peptides, to profound structural polymorphisms in genes and proteins that can nullify transcription or translation of one allelic variant and result in the complete abrogation of its presentation by MHC.
次要组织相容性抗原（mHAgs）是一类多样的与主要组织相容性复合体（MHC）结合的肽，在异基因造血干细胞移植后诱导有害的移植物抗宿主病（GVHD）或产生有益的移植物抗肿瘤（GVT）效应的过程中起关键作用。mHAgs是等位基因多态性的结果，这导致移植供体和受体之间MHC呈递的肽表位存在差异。这种供体/受体等位基因差异范围广泛，从MHC呈递的肽之间微小的氨基酸侧链差异，到基因和蛋白质中深刻的结构多态性，后者可使一个等位基因变体的转录或翻译无效，并导致其无法由MHC呈递。
